Preclinical Alzheimer Disease Drug Development: Early Considerations Based on Phase 3 Clinical Trials

SUMMARY: The number of people in the United States living with Alzheimer disease (AD) is growing, resulting in significant clinical and economic impact. Substantial research investment has led to drug development in stages of AD before symptomatic dementia, such as preclinical AD. Although there are...

Descripción completa

Detalles Bibliográficos
Autores principales: Hung, Anna, Schneider, Monika, Lopez, Marianne Hamilton, McClellan, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Viewpoints
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391091/
https://www.ncbi.nlm.nih.gov/pubmed/32584672
http://dx.doi.org/10.18553/jmcp.2020.26.7.888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391091/
https://www.ncbi.nlm.nih.gov/pubmed/32584672
http://dx.doi.org/10.18553/jmcp.2020.26.7.888

Ejemplares similares